M Bio Technology Inc.
Novel diagnoses, prevention and therapeutics technologies for mycoplasma infectious diseases (MID)
Business information
Company name
M Bio Technology Inc.
Established
2005
Location
Tokyo, JP
Spinout from
Other location(s)
Chiba, JP
Technology validation
TRL
5
Value of patent(s)
Over $3m
Business stage
Series B stage / global alliance
Target exit
Licensing out
Next investment requirement
$10-20m
Message to the business partners
M Biotech has key patents for the structure of glycolipid on mycoplasma membrane surfaces as well as its synthesis methodology. These technologies could be applied both for high sensitive diagnoses and vaccine development with applying the glycolipid-antigen to produce its antibody. M Biotech encourages global business expansion with identifying the business and technical partners.
Company URL
Key literatures
Synthesis and absolute structures of Mycoplasma pneumoniae β-glyceroglycolipid antigens
Chemosynthetic homologues of Mycoplasma pneumoniae β-glycolipid antigens for the diagnosis of mycoplasma infectious diseases
Detection of serum antibodies against phosphocholine-containing aminoglycoglycerolipid specific to Mycoplasma fermentans in HIV-1 infected individuals